A highly sensitive method was developed to measure naloxone and its metabolite nornaloxone in human plasma, urine, and human liver microsomes (HLM). Naltrexone-d 3 and oxymorphone-d 3 were used as respective internal standards. Solid-phase extraction, using mixed mode extraction columns and 0.1 M phosphate buffer (pH 5.9), was combined with high-performance liquid chromatography interfaced by electrospray ionization to tandem mass spectrometry. The calibration range in plasma was 0.025 to 2 ng/mL for naloxone and 0.5 to 20 ng/mL for nornaloxone. It was 10 to 2000 ng/mL in urine and 0.5 to 20 ng/mL in HLM for both. Enzymatic hydrolysis of urine was optimized for 4 h at 40°C. Intra-and interrun accuracy was within 15% of target; precision within 13.4% for all matrices. The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone. Analytes were stable in plasma and urine for up to 24 h at room temperature and in plasma after three freeze-thaw cycles. In human subjects receiving 16 mg buprenorphine and 4 mg naloxone, naloxone was detected for up to 2 h in all three subjects and up to 4 h in one subject. Mean AUC 0-24 was 0.303 ± 0.145 ng/mL·h; mean C max was 0.139 ± 0.062 ng/mL; and T max was 0.5 h. In 24-h urine samples, about 55% of the daily dose was excreted in either conjugated or unconjugated forms of naloxone and nornaloxone in urine. When cDNAexpressed P450s were incubated with 20 ng of naloxone, nornaloxone formation was detected for P450s 2C18, 2C19, and 3A4. Naloxone utilization exceeded nornaloxone formation for 2C19 and 3A4, indicating they may produce products other than nornaloxone. These results demonstrate a new method suitable for both in vivo and in vitro metabolism and pharmacokinetic studies of naloxone.
Introduction
Naloxone (Figure 1 ), (5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl) morphinan-6-one, is a mu-receptor antagonist (1-4) used mainly for the treatment of opioid overdose and to reverse opioid-induced depression following surgery (5) (6) (7) . The use of naloxone in a combination sublingual tablet containing buprenorphine at a fixed ratio of 4:1 (buprenorphine/naloxone) for the treatment of opioid dependence has recently been approved by the U.S. Food and Drug Administration. The purpose of the addition of naloxone to a buprenorphine tablet is to prevent diversion of buprenorphine for illicit intravenous use (8) . Because of the low doses of naloxone (2-6 mg) used in maintenance therapy, sensitive analytical methods are required. Naloxone is metabolized by N-dealkylation to nornaloxone (also known as noroxymorphone, Figure 2) , reduction of the 6-oxo group to naloxol, as well as glucuronidation of naloxone and the two metabolites (9) (10) (11) .
There are several published methods for the determination of naloxone concentrations in biological fluids. Radioimmunoassay (12) was developed in the 1970s; it is sensitive but has selectivity limitations. Gas chromatography with 63 Ni electron-capture detector (13) , high-performance liquid chromatography (HPLC) with UV or variable-wavelength detector (14, 15) , and HPLC with electrochemical detection have since been developed (16) (17) (18) . The reported lower limit of quantitation (LLOQ) of all these methods are in a range from 0.5 to 10 ng/mL for naloxone. We previously published an HPLCelectrospray ionization-tandem mass spectrometric method (ESI-MS-MS) designed to measure the coformulant, naloxone, along with buprenorphine and norbuprenorphine with an LLOQ of 0.1 ng/mL (19) . None of these methods measured nornaloxone. This article describes a new method that measures the concentration of both naloxone and its metabolite nornaloxone. It was fully validated in human plasma with matrix cross validation to human urine and human liver microsomes (HLM). The application of this method for in vivo and in vitro metabolism studies of naloxone to nornaloxone in humans is also presented. From 0 to 4 min, acetonitrile increased from 6 to 76%, was held at 76% for 30 s, then returned to 6% in another 30 s. The column was then equilibrated with 6% acetonitrile for 7 min. The total run time was 12 min with a flow rate of 0.2 mL/min. Autosampler temperature was set at 10°C, and column temperature was set at 22°C. Injection volume was 15 µL.
A Finnigan/Thermo Quest TSQ triple-stage quadrupole MS was used for analysis. It was equipped with a Gateway GP6-450 computer with Windows NT operating system and Xcalibur (v 1.1) operating software. The HPLC was interfaced to the MS by means of an ESI manifold. The instrument was operated under selective reaction monitoring mode. The capillary temperature was 250°C, and ESI spray voltage was set at 4.5 kV. High purity N 2 was used for both sheath gas and auxiliary gas that were set at 70 psi and 15 flow units, respectively. High purity Ar (2.5 mTorr) was used for collision gas. The Xcalibur software was used for the setup and operation of sequence lists and LC Quan (within the Xcalibur software) was used for batch quantitation. The m/z 328 (MH + ) to 310 and 345 to 327 selected reaction monitoring transitions were used to analyze naloxone and its internal standard naltrexone-d 3 . The m/z 288 (MH + ) to 270 and 305 to 287 transitions were used to analyze nornaloxone and its internal standard oxymorphone-d 3 . The concentration of naloxone and nornaloxone was determined by the peak-area ratio of the analyte and its internal standard. These were compared to the calibration curve that was generated from the analysis of plasma or urine fortified with known concentrations of the analyte and its internal standard.
Quality control (QC)
QC samples and calibrators were prepared by different staff members. All calibrators were run in duplicate. In plasma, they were 0.025, 0.05, 0.075, 0.1, 0.15, 0.25, 0.5, 1.0, and 2.0 ng/mL for naloxone and 0.5, 0.75, 1.0, 1.5, 2.5, 5.0, 10, and 20 ng/mL for nornaloxone. In urine, both analytes were run at 10, 25, 100, 500, 750, 1000, 1500, and 2000 ng/mL. For HLM analysis, calibrators were prepared at 0.5, 0.75, 1.0, 1.5, 2.5, 5.0, 10, and 20 ng/mL. One set of calibrators was run at the beginning of the batch and one set at the end. Calibrators were deleted from the curve if they deviated more than ±15% (±20% at the LLOQ level) from target. A valid run should not have more than 25% of calibrators deleted. QCs were run at a minimum of n = 3 for each QC concentration (low, medium, and high). QC concentrations were selected based on the following criteria: low QC is no more than three times the LLOQ concentration, the high QC is 70-80% of the upper limit of quantitation (ULOQ). For the medium QC, this study used approximately 35% of the ULOQ. QCs were run at the beginning, middle, and end of each sample batch. QCs were acceptable if they were within ±15% of target. For a run to pass, at least two-thirds of all QCs must pass, and at least one replicate at each QC concentration should pass.
Method validation
Method validation experiments were conducted to meet guidelines for bioanalytical method validations specified by The U.S. Food and Drug Administration (20) . A full validation was performed in human plasma; only partial validation is required for changes in matrix. Partial validation experiments performed for urine were specificity, intra-and interrun precision and accuracy, and room temperature matrix stability. For HLM, only specificity and intrarun precision and accuracy experiments were performed.
Specificity is the ability of an analytical method to differentiate and quantify the analyte in the presence of other components in the matrix (i.e., matrix selectivity). Specificity was evaluated for all three matrices by using six different sources from each matrix. For each source, three replicates were spiked with internal standard only; one replicate was spiked with internal standard and analyte at LLOQ. The primary evaluation was to compare the mean peak-area ratio of any signal (often obtained by forced integration) at the retention time of analyte to its internal standard for each source with the mean peak-area ratio of the six LLOQ samples. The mean peak-area ratio of the three internal standard only samples should not exceed 20% of the mean peak-area ratio of the six LLOQ samples. The results of this experiment were used in part to determine the LLOQ.
Recovery was determined at the three QC concentrations (n = 5 each). Internal standard recovery was determined at its concentration of use. Analytes were fortified in one set of blank plasma and one set without matrix. The plasma set went through extraction and then were dried down along with the set without matrix. Both sets were then reconstituted and analyzed. Percent recovery was determined at each concentration by dividing the average peak area of extracted samples by the average peak area of unextracted samples and multiplying by 100.
Intrarun precision and accuracy were performed for all three matrices using LLOQ and the three QC concentrations. LLOQ samples were prepared in the same six sources used for the specificity study. QCs were run at n = 5 for each concentration. Acceptance criteria for accuracy are mean results within 15% of target value (20% for LLOQ) and precision expressed as %CV (coefficient of variation) within 15% (20% for LLOQ).
Interrun precision and accuracy were determined in plasma and urine using two additional runs of QCs at n = 5 for a total of 15 measurements for each QC concentration. Acceptance criteria for accuracy are mean results within 15% of target value and precision for %CVs within 15%. %CV was calculated by using variance results from one-way analysis of variance (ANOVA) for better estimate of interrun precision (21) . For each concentration, the three separate runs (n = 5 each) were compared. One-way ANOVA considers both between-and within-group variations. Precision (S t ) is then defined by the following equation using both mean square between groups (MS bg ) and mean square within group (MS wg ) (21):
where X is the grand mean, which is the total of all data value divided by total sample size, and n is the number of replicates in each group.
Stability experiments were performed at low and high QC concentrations with n ≥ 3. Room temperature stability evaluates QCs that were stored at room temperature for 24 h prior to extraction. Freeze-thaw stability evaluates QCs removed from the freezer to thaw unassisted, then back in freezer for at least 12 h, which is repeated twice for a total of three cycles prior to analysis. For processed sample stability, analyzed QCs were stored either on the autosampler or at -20°C until they were reanalyzed with freshly extracted calibrators and QCs. Acceptance criteria are mean results within 15% of target. To determine stock solution stability, stock solutions prepared at the beginning of the method validation were compared to stock solutions prepared at the conclusion of the validation experiments. Room temperature stock stability was also evaluated by comparing freshly made stock solution at the day of analysis with aliquots held at room temperature for a period of time. Acceptance criteria are that mean peak-area counts of old stock are within 15% of freshly made stock.
In vivo specimens
The study subjects (n = 3) were patients who were maintained for at least two weeks on daily sublingual doses of 16 mg buprenorphine/4 mg naloxone (22, 23) . Blood was drawn into heparinized tubes at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h over a 24-h dosing interval, and plasma was collected and stored frozen until analysis. Urine was also collected into plastic containers and pooled during the entire 24 h, the volume measured, and aliquots taken for frozen storage prior to analysis. The plasma and urine data presented here are not from the same three study subjects. All subjects provided informed consent and were compensated for participation in the studies. All protocols had received prior approval by the local institutional review board.
In vitro incubations
Incubations of naloxone with HLM and cDNA-expressed cytochrome P450s (P450) were performed using our previously described incubation conditions (24, 25) . HLM were prepared using the method described by Nelson et al. (26) with the first centrifugation at 9000 × g, the homogenization buffer containing 0.25 M sucrose, and 10 strokes of homogenization. The protein content was determined by the method of Lowry et al. (27) . Three HLMs were used. Incubation was carried out using 0.5 mg/mL microsomal protein and 100 ng/mL naloxone in an incubation buffer (0.1 M phosphate buffer, pH 7.4 with 1.0 mM EDTA and 5.0 mM MgCl 2 ) with NADPH-generating system (10 mM glucose-6-phosphate, 1.2 mM NADP, and 1.2 units of glucose-6-phosphate dehydrogenase, NADPH-GS). The total volume was 0.5 mL. The reaction was initiated by adding the NADPH-GS and incubating at 37°C for 30, 60, and 90 min in a water bath shaker, then terminated by addition of 200 µL of ice-cold methanol. Naloxone was incubated with microsomes prepared from insect cells transfected with cDNAs encoding for human P450s 1A2, 2A6, 2B6, 2C8, 2C9*1, 2C18, 2C19, 2D6*1, 2E1, 3A4, 3A5, and 3A7 (BD Biosciences, Franklin Lakes, NJ). Supersomes that coexpressed cytochrome b 5 were used where available (not for 1A2, 2C18, and 3A5). Naloxone (100 ng/mL) was incubated with 25 pmol of P450 at 37°C for 60 min in the incubation buffer (described earlier) with final incubation volume of 200 µL. Further experiments were conducted with 2C18 and 2C19 at naloxone concentrations of 25, 50, and 100 ng/mL with 30 min incubation. The reaction was initiated by adding a NADPH-GS and terminated by addition of 200 µL of ice-cold methanol. Human liver tissue was obtained from Tissue Transformation Tech. (Edison, NJ).
Results and Discussion

Spectra and chromatography
The mass spectrum of naloxone, nornaloxone, and their internal standards, naltrexone-d 3 and oxymorphone-d 3 , obtained by infusing 10 µg/mL neat standard directly into the source at 0.01 mL/min, are shown in Figures 1 and 2 . The most abundant fragments that correspond to a loss of water from both analytes and their internal standards were chosen as the quantitative fragment. The ESI fragmentations of naloxone and naltrexone-d 3 are similar to our previous method (19) . Those for nornaloxone and oxymorphone-d 3 have not been previously presented. As this method was developed primarily for use in controlled pharmacokinetic studies, no qualifier ion was used; however, one should be included in forensic analyses, and the molecular ions might serve such a purpose.
Selected ion chromatograms of blank plasma or urine fortified with internal standard demonstrate that no significant peaks exist at the retention time for naloxone (~4.4 min) and nornaloxone (~2.5 min) in plasma ( Figure 3A) ; there is a small peak in blank urine where naloxone elutes, but the peak area was much lower than the LLOQ peak, so this did not affect specificity ( Figure 3B ). Typical peak shapes and signal-to-noise ratios for extracts of plasma fortified with 0.025 ng/mL naloxone and 0.5 ng/mL nornaloxone (LLOQ) and their internal standards (naltrexone-d 3~4 .85 min; oxymorphone-d 3~2 .65 min) are shown in Figure 3C and of urine fortified with 10 ng/mL naloxone and nornaloxone (LLOQ) and their internal standard are shown in Figure 3D . These peaks demonstrate the lowest LLOQ to date in plasma, which provides us valuable tools for low dose naloxone pharmacokinetic studies. All chromatograms show Gaussian peak shape with sufficient signalto-noise and good separation. * Intrarun data were obtained from a single run at n = 5 for three QC concentrations and n = 6 for LLOQ concentration (each in six different lots). † Interrun data were obtained from three different analytical runs at n = 5 per run. Interrun %CV was calculated from the use of one-way ANOVA.
Aliquots of pooled drug-free human plasma, urine, and HLM were extracted using the method described earlier. An ion suppression experiment was performed using continuous postcolumn infusion (10 µL/min) of a standard solution containing the analytes of interest and its internal standards (250 ng/mL) using a syringe pump. After injecting the drug-free extracted blank samples into the LC system, a drop in the constant baseline at analytes retention time would indicate ion suppression (28) . No matrix associated suppression was observed during the retention time for the analytes (Figure 4 ). 
Specificity
Specificity for naloxone and nornaloxone were determined in plasma, urine, and HLM as described in the experimental method section. Mean ratios relative to the mean LLOQ ranged from 4.32% to 7.60% with a mean of 5.94% for naloxone and from 5.67% to 13.5% with a mean of 9.61% for nornaloxone in human plasma. In urine, it ranged from 0.56% to 0.94% with a mean of 0.74% for naloxone and from 4.81% to 9.04% with a mean of 6.79% for nornaloxone. In HLM, it ranged from 2.73% to 17.5% with a mean of 8.62% for naloxone and from 12.1% to 19.6% with a mean of 16.3% for nornaloxone. These experiments establish sufficient specificity for the use of an LLOQ at 0.025 ng/mL for naloxone and 0.5 ng/mL for nornaloxone in plasma, at 10 ng/mL in urine, and 0.5 ng/mL in HLM for both analytes.
These specificity experiments only show the selectivity of the method versus endogenous components in the matrices tested. They do not show selectivity from other drugs. To evaluate interference from exogenous compounds, four sets of blank plasma (n = 3) were fortified with groups of representative psychoactive drugs along with internal standards and analytes at the LLOQ. Another set was fortified with just analytes at the LLOQ and internal standards. Deviation from the LLOQ target of ±20% or less indicates no interference, which was the case for the drugs tested in this study (Table I) .
Recovery
Recovery was evaluated at three QC concentrations. Mean recovery of naloxone was 69.2%, and for nornaloxone it was 32.0%. For naloxone alone, recoveries between 45% and 90% have been reported with either liquid-liquid or solid-phase extractions (13) (14) (15) (16) (17) (18) . Recovery for nornaloxone has not been previously reported. The polarity difference between naloxone and nornaloxone presents a real challenge for extraction. Solidphase extraction with an extraction column that has both hydrophobic and ionic attractions was chosen as the best compromise for both compounds. The use of triethylamine instead of ammonium hydroxide in the elution solution greatly im- Table IV proved the selectivity and consistency of the extraction process (14) . The recovery of internal standards, naltrexone-d 3 , and oxymorphone-d 3 , at their concentration of use, 1 ng/mL and 5 ng/mL, were 84.4% and 55.4%, respectively.
Precision and accuracy
Intra-and interrun precision and accuracy experiments are summarized in Table II . The intrarun accuracies of the LLOQ in all matrices were within 15% of target with intrarun precisions within 13.4%. The intrarun accuracies of other QCs were within 10.7% of target with intrarun precision within 11.4%. Interrun accuracies of the QCs were within 12.7% of target with interrun precisions within 12.1%.
Stability
A series of studies were conducted to determine the stability of naloxone and nornaloxone in human plasma and urine. The experiments emphasized the storage conditions for everyday analysis. Results (Table III) show that naloxone and nornaloxone are both stable in human plasma for up to 24 h at room temperature for 468 days, at -20°C, and after three freeze-thaw cycles. Similar experiments show that they are also stable in urine for up to 24 h at room temperature (Table III) . Processed samples were stored at either -20°C for seven days or for three days on the autosampler with original caps. Under both storage conditions, mean QC results were within 15% of target concentration (Table III) . Results also indicate that naloxone and nornaloxone are both stable in methanol for up to 174 days at -20°C and 17 h at room temperature (Table III) . We conducted the most comprehensive stability study thus far for both naloxone and nornaloxone in different matrix and storage conditions. For naloxone alone, some processed sample stability data has been previously presented (18, 19) as well as plasma matrix stability (19) . Our study was able to extend the plasma storage time (at -20°C) for naloxone from 238 days (19) to 468 days.
Plasma pharmacokinetics of naloxone
The results of naloxone concentration versus time for three individuals are shown in Figure 5 . Plasma naloxone concentration peaked and decreased rapidly with time. Naloxone was detected in plasma from all three subjects for up to 2 h and in one of the three subjects for up to 4 h. The mean ± SD AUC 0-24 was 0.303 ± 0.145 ng/mL·h; mean ± SD C max was 0.139 ± 0.062 ng/mL; and T max was 0.5 h for all. Naloxone is known for its low bioavailability when taken via the sublingual route. The high sensitivity of our new method enables us to consistently gather AUC data for naloxone. Plasma nornaloxone concentrations were less than 0.5 ng/mL (LLOQ) at all time points at this dosage. Although previous studies on sublingual formulations of buprenorphine and naloxone were able to detect naloxone at certain time points (11, 19, 29) , this is the first time sufficient time points have been collected to allow determination of plasma AUCs for this formulation of naloxone.
Urinary excretion
A 200-µL aliquot of each urine sample was treated with 1000 units of β-glucuronidase in 200 µL of 0.1 M sodium acetate buffer (pH 5). The mixture was incubated at 40°C for 0, 1, 3, 5, and 16 h. Figure 6 shows hydrolysis time versus mean naloxone and nornaloxone concentration with optimal hydrolysis at 4 h. Using 4-h concentration data (an average of 3-and 5-h data) and total volume of urine collected, the percent of daily dose of naloxone excreted can be calculated (Table IV) . About 55% of the daily dose was excreted in either conjugated or unconjugated forms of naloxone and nornaloxone. A previous study also indicated naloxone urinary excretion of 24-37% in the first 6 h and very little after 48 h (30) .
In vitro incubation of naloxone with HLM and recombinant human P450s Figure 7 shows the formation of nornaloxone with incubation time in three HLM. Two of the three HLM formed more nornaloxone than the other one, which may be caused by the difference in the amounts of P450 enzymes in each liver. Figure 8A shows the measured nornaloxone formation, and Figure 8B shows naloxone utilization after incubation of naloxone with cDNA expressed human P450s. From the figures, it can be seen that 2C18 and 2C19 are the major enzymes involved in the metabolism of naloxone to nornaloxone; 3A4 and 2D6 displayed activity but at much lower levels. Due to higher concentrations of 3A4 in human liver, it may still significantly contribute to naloxone metabolism. At the concentration used in this experiment (100 ng/mL), nornaloxone formation was similar to naloxone used in 2C18 but less so in 2C19. To further explore this difference, the experiments were repeated at additional concentrations ( Figure 9 ). 2C18 produced the same amount of nornaloxone as the amount of naloxone consumed across concentrations (Figure 9 ). 2C19 consumed more naloxone than the amount of nornaloxone produced across concentrations (Figure 9 ), which indicate its involvement in alternate routes of naloxone metabolism. A similar situation was found for P450 3A4 at the one concentration studied ( Figure  8 ). To the best of our knowledge, this represents the first time specific P450 involvement has been demonstrated for naloxone N-demethylation.
Conclusions
The results of these studies show that naloxone and nornaloxone can be quantitated using solid-phase extraction and HPLC-ESI-MS-MS from a 1.0-mL aliquot of human plasma/ HLM or 200-µL of human urine with acceptable precision and accuracy down to an LLOQ of 0.025/0.5 ng/mL for plasma, 0.5 ng/mL for HLM, and 10 ng/mL for urine. These experiments also determine the following limits for experimentation with naloxone and nornaloxone in these matrices. Room temperature storage of plasma or urine was at least 24 h and freezethaw of plasma at least three cycles. To permit reinjection of samples, they can be stored at least seven days at -20°C or three days on the autosampler. The stock solutions for naloxone and nornaloxone can be at least 174 days old in methanol and can be stored at room temperature for at least 17 h in methanol. These limits are current and could be extended by further experimentation. This method has been validated for both in vivo and in vitro studies. Using this method, we were able to follow naloxone concentration in plasma, determine plasma AUCs and the percent of daily dose excreted in urine for sublingual doses, and identify the involvement of P450 2C18, 2C19, and 3A4 in naloxone metabolism.
